AbbVie Disputes $3M AndroGel Verdict In MDL Bellwether
Law360 (April 24, 2018, 3:45 PM EDT) -- AbbVie Inc. asked an Illinois federal court Monday to grant a new trial, enter a judgment against the patient who brought suit or overturn a $3.2 million verdict that found the drugmaker's testosterone replacement therapy AndroGel caused the patient's heart attack, saying the jury's finding was contradictory.
The jury in the latest bellwether case in multidistrict litigation over testosterone replacement therapies found in favor of patient Jesse Mitchell on his claim the company was negligent but for AbbVie on strict liability and fraudulent misrepresentation claims. These findings are inconsistent, however, because the negligence and strict liability claims both required Mitchell to demonstrate the same...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!